Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MTA1 CRISPR/Cas9 KO Plasmid (h): sc-400942
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MTA1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MTA1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MTA1 Antibody (E-12): sc-373765
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MTA1 CRISPR/Cas9 KO Plasmid (h) | sc-400942 | 20 µg | $397.00 |
Overview
MTA1 (metastasis associated 1) encodes a chromatin-associated coregulator and a key component of the NuRD (nucleosome remodeling and deacetylase) complex, integrating ATP-dependent nucleosome remodeling with histone deacetylation to shape transcriptional programs. Through interactions with HDAC1/2, CHD4, and sequence-specific transcription factors, MTA1 influences epithelial–mesenchymal transition, DNA damage responses, hormone receptor signaling, and cell-cycle regulation. Altered MTA1 expression or activity has been linked to tumor progression and invasive phenotypes across multiple cancer types, where it can modulate oncogenic and differentiation pathways. As a nuclear regulator of chromatin state, MTA1 is frequently studied in transcriptional repression/activation dynamics, epigenetic plasticity, and mechanisms of metastasis-associated gene expression.
MTA1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MTA1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MTA1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MTA1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MTA1 protein expression.
This CRISPR knockout system enables efficient generation of MTA1-deficient cell models for investigation of MTA1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MTA1 exon(s) critical for MTA1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MTA1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MTA1 CRISPR/Cas9 KO Plasmid (h) and MTA1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MTA1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MTA1 HDR Plasmid (h) and MTA1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MTA1 homology arms to support homology-directed repair at defined MTA1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.